We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Reintroduction of key legislation presented late last year that would establish a clear and scientifically sound pathway for the approval of follow-on biologics would save the federal government about $14 billion in Medicare costs over the next decade, according to a new report by the Pharmaceutical Care Management Association (PCMA).
Primary care trusts in the UK are being urged to recommend generic versions of statins to keep the high cost associated with the drugs under control, data in a new report shows.
A Canadian court ruling that dismissed an appeal request by Apotex signals another defeat for the generic drugmaker in its efforts to market generic clopidogrel bisulfate.
A key senator has begun the 110th Congress introducing legislation aimed at removing obstacles that slow generic drug entry into the market, his office announced.
A key senator has begun the 110th Congress introducing legislation aimed at removing obstacles that slow generic drug entry into the market, his office announced.
Ranbaxy Pharmaceuticals won final FDA approval to market atenolol, a generic version of AstraZeneca’s hypertension drug Tenormin, the company announced Jan. 2.
Primary care trusts in the UK are being urged to recommend generic versions of statins to keep the high cost associated with the drugs under control, data in a new report shows.
A Canadian court ruling that dismissed an appeal request by Apotex signals another defeat for the generic drugmaker in its efforts to market generic clopidogrel bisulfate.